The Genentech
Commitment
A Strong Legacy in Biotechnology
Since 1976, Genentech has been a leader in the field of biotechnology. We discover, develop, manufacture, and commercialize medicines to treat patients with serious and life-threatening medical conditions.
Our Pledge to Progress
With our reinvestments in revenue, we have helped to maintain our innovations and are dedicated to creating more breakthroughs in ophthalmology.
CHf=confoederatio helvetica franc.
Success by the Numbers
Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer, the first medicine for primary progressive multiple sclerosis, and the first FDA-approved antibody therapy for various retinal diseases.
medicines on the market addressing advanced, unmet medical needs
FDA-granted breakthrough therapy designations (BTDs); nearly 20% of all approved BTDs in the US
billion dollars in R&D investment in 2019 (#1 of any pharmaceutical/biotech company)
Since 1985, Genentech has donated more than $3.5 billion in free medicine.
>2.2 million patients able to access Genentech medicines through Genentech Access Solutions
>25,000 US employees across Genentech and Roche Diagnostics
785k square feet of research—one of the largest biologics research facilities in the world
Going Beyond Drug Development in Ophthalmology
At Genentech, we are committed to innovating beyond the current standards of care to transform how patients experience ophthalmic care.
Ways we are looking toward the future
- Utilizing artificial intelligence (AI) technology for predictive treatment and retreatment
- Leveraging genomics and imaging research pipeline
- Partnering with American Academy of Ophthalmology (AAO) and Intelligent Research in Sight (IRIS) to improve disease understanding
- Promoting health equity and diversity in science, technology, engineering, and math (STEM) through the Health Equity Innovation Fund and the Diverse Future of STEM Fund
- Investing $90 million toward patient support, STEM education, and health equity programs
Ways we are looking toward the future
- Utilizing artificial intelligence (AI) technology for predictive treatment and retreatment
- Leveraging genomics and imaging research pipeline
- Partnering with American Academy of Ophthalmology (AAO) and Intelligent Research in Sight (IRIS) to improve disease understanding
- Promoting health equity and diversity in science, technology, engineering, and math (STEM) through the Health Equity Innovation Fund and the Diverse Future of STEM Fund
- Investing $90 million toward patient support, STEM education, and health equity programs